SAN FRANCISCO (GenomeWeb) – Researchers at the University of Pittsburgh Medical Center have developed a next-generation sequencing-based test that can help clinicians spot cancerous pancreatic cysts by identifying mutations found in DNA from the cyst fluid.

Approximately 15 percent of pancreatic cancers develop from common cysts, but there are currently no good methods to differentiate benign from cancerous cysts.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.